- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05780931
Réhabiliter la perte de vision chez les anciens combattants atteints de dégénérescence maculaire liée à l'âge (AMD)
Développement de nouvelles approches pour la réhabilitation de la perte de vision chez les vétérans atteints de dégénérescence maculaire liée à l'âge
This study will help develop new methods of rehabilitating Veterans with vision loss due to Age-related macular degeneration.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The purpose of this research study is to develop new and improved methods of helping vision-impaired Veterans see better by using hands as "seeing eyes". This study will focus on Veterans with a common form of eye disease called age-related macular degeneration that affects older individuals.
Type d'étude
Contacts et emplacements
Lieux d'étude
-
-
Georgia
-
Augusta, Georgia, États-Unis, 30904-6258
- Charlie Norwood VA Medical Center, Augusta, GA
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Veterans with vision loss caused by age-related macular degeneration
La description
Inclusion Criteria:
- The subject is a Veteran
- The subject has best-corrected visual acuity (BCVA) of 20/40 or worse in each eye, as determined by the standard Charlie Norwood VA Medical Center (CNVAMC) optometric tests
- The subject has visual field deficit of 10O in either eye as determined by the Octopus 900 perimetry (Haag-Streit Diagnostics, Haag-Streit USA, Mason, OH) administered by CNVAMC. (When the deficit/s are binocular, they do not necessarily have to be in binocularly corresponding positions)
- The subject has received a formal clinical diagnosis of age-related macular degeneration (AMD) in one or both eyes (binocular AMD does not necessarily have to be in binocularly corresponding positions)
- The subject has visual deficit in either eye (wavy lines and/or missing/darkened areas on the grid) determined by the standard Amsler Grid Test
- The subject has not yet started any rehabilitative treatment for AMD-related vision loss
- Both eyes of the subject are otherwise age-appropriately stable, and neither eye has any other visual defects, as determined by the standard CNVAMC ophthalmological examination
- The subject must be able to understand the nature and individual consequences of the study
- The subject must be able to provide signed and dated informed consent before start of any participation in the study procedures (11)Women with childbearing potential must test negative for pregnancy using a standard urine test prior to participating in each functional magnetic resonance imaging (fMRI) procedure. (This exclusion criterion is mandated by the Augusta University Institutional Review Board [AU IRB], which also serves as the IRB of record of the CNVAMC. It is intended as an extra precautionary measure to help ensure the health and safety of this vulnerable population. The proposed study will comply with this requirement.)
Exclusion Criteria:
- According to the patient's VA clinical records, the patient has one or more clinically diagnosed neurological disorder
- According to the patient's VA clinical records, the patient has one or more clinically diagnosed cognitive deficits
- According to the patient's VA clinical records, the patient has been clinically diagnosed with a psychiatric disorder that would make it unduly uncomfortable or otherwise clinically inadvisable for the subject to participate in the study
- According to the patient's VA clinical records, according to the patient, or both, the patient has motor disorder/s that would make it unduly uncomfortable or otherwise clinically inadvisable for the subject to participate in the study
- According to the patient's VA clinical records, according to the patient, or both, the patient has an MR-incompatible implant and/or another condition (e.g., claustrophobia) that would make it inadvisable for the subject to participate in MR imaging or any other study procedure
- The patient does not understand the informed consent information and/or the standard study instructions in spoken or written English, and/or is unable to follow study instructions. [The purpose of this exclusion criterion, required by the AU IRB, is to help ensure that the subjects adequately understand all the information relevant to providing informed consent, as well as the study instructions.]
- Inability to give informed consent to participate in the study
- Pregnancy, as determined by a standard urine test for pregnancy
- Participation in other study/studies including an investigational drug or device during the present study
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: CASE_CONTROL
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Treatment Group
This is the group of study subjects which will undergo study-related rehabilitation procedures. |
Study-specific rehabilitation procedures will systematically manipulated the spatial or temporal synchrony (or coordination) of visual vs. haptic inputs that the subjects receive.
Autres noms:
|
|
Control Group
This is the group of study subjects which will undergo control (sham) rehabilitation procedures (in addition to all their regularly scheduled treatments and interventions). |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Accuracy of object recognition
Délai: 6-10 weeks
|
This outcome will be measured as the accuracy (% correct) with which the study subjects recognize the text objects before, during and after their participation in the study procedures. |
6-10 weeks
|
|
Response of brain regions of interest (ROI) as reflected in the BOLD (blood oxygenation level-dependent) response
Délai: 6-10 weeks
|
This outcome will be measured as changes (if any) of the BOLD responses of brain ROIs before, during and after their participation in the study procedures. |
6-10 weeks
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Jay Hegde, PhD, Charlie Norwood VA Medical Center, Augusta, GA
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- C4099-P
- I21RX004099-01A1 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .